The Company, a global leader in the protein biotherapeutics industry, offers Local Empowerment for Advocacy Development (LEAD) grants. The grants help improve the quality of life for people with rare disease who utilize plasma-derived or recombinant therapies for bleeding disorders, immune disorders, Alpha-1 deficiencies, or other conditions. The Company partners with patient organizations to address important public policy issues and grants are awarded twice annually to help patient organizations achieve their advocacy objectives. They can be used to further an existing advocacy initiative, provide assistance in developing a new initiative, build a grassroots database, and other projects. Applicants must be currently addressing a specific advocacy issue or intending to address such an issue. An online application is available along with other information on the Company’s Web site. Applications are due October 31 and April 30.
More Information: Login or Join/Subscribe